Panacea Biotec Secures US$8.205 Million Order from UNICEF for Polio Vaccine Supply in 2028
Panacea Biotec Ltd has received a Letter of Award from the United Nations International Children's Emergency Fund (UNICEF) to supply bivalent Oral Polio Vaccine (bOPV). The contract, which falls under an existing Long-Term Agreement, is valued at US$8.205 million, equivalent to approximately Rs.78.24 Crore and is set for execution in Calendar Year 2028.This new order pertains to the supply of bivalent Oral Polio Vaccine (bOPV) in both 10 and 20 dose presentations to UNICEF. The contract is part of a broader Long-Term Agreement established previously, which also covered supplies during Q2 CY2026 and CY2027.
The award represents an international order from UNICEF for the supply of bOPV during Calendar Year 2028.
Key details regarding the transaction are as follows:
| Particular | Details |
|---|---|
| Awarding Entity | United Nations International Children's Emergency Fund (UNICEF) |
| Nature of Contract | Supply of Bivalent Oral Polio Vaccine (bOPV) |
| Time Period for Order | Calendar Year 2028 |
| Consideration/Value | US$8.205 million (Approx. Rs.78.24 Crore) |
| International Entity Status | International |
Panacea Biotec Ltd confirmed that the award received on August 4, 2026, involves no interest from the company's promoter or promoter group in the awarding entity. Furthermore, the order does not fall under related party transactions.
PANACEABIO Stock Price Movement
Shares of Panacea Biotec Limited are edging higher to ₹428.8 as of 9:43 AM today, gaining ₹9.40 or 2.24%. The stock maintains a healthy market flow, with 91,166 shares traded in the live session so far.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.